Agonistic and antagonistic targeting of immune checkpoint molecules differentially regulate osteoclastogenesis.

ABSTRACT:

Introduction

Immune checkpoint inhibitors are used in the treatment of various cancers and have been extensively researched with regard to inflammatory and autoimmune diseases. However, this revolutionary therapeutic strategy often provokes critical auto-inflammatory adverse events, such as inflammatory reactions affecting the cardiovascular, gastrointestinal, nervous, and skeletal systems. Because the function of these immunomodulatory co-receptors is highly cell-type specific and the role of macrophages as osteoclast precursors is widely published, we aimed to analyze the effect of immune checkpoint inhibitors on these bone-resorbing cells.

Methods

We established an in vitro model of osteoclastogenesis using human peripheral blood mononuclear cells, to which various

SUBMITTER: Brom VC 

PROVIDER: S-EPMC9931766 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature